meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced (laHNSCC)
laHNSCC - (neo)adjuvant (NA)
laHNSCC - 1st line (L1)
1
laHNSCC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
versus all
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
avelumab alone
title
placebo
title
JAVELIN Head and Neck 100, 2021 NCT02952586 laHNSCC - 1st line (L1) 350/347
Pathology:
laHNSCC - 1st line (L1);
laHNSCC - 1st line (L1)
JAVELIN Head and Neck 100, 2021
avelumab alone
1
T1
placebo
0
T0